Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer

Phase 2

Conditions: Squamous Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: cisplatin
Radiation: thoracic radiation therapy
Drug: docetaxel

First Posted Date: 2016-06-01

Last Posted Date: 2016-11-25

Lead Sponsor: First People's Hospital of Hangzhou

Target Recruit Count: 54

Registration Number: NCT02787473

Locations: 🇨🇳
Hangzhou First People's Hospital, Hangzhou, Zhejiang, China

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Soft Tissue Sarcoma
Colon Cancer
Solid Tumor
Breast Cancer
Cholangiocarcinoma

Interventions: Drug: LY3039478
Drug: LY3023414
Drug: Abemaciclib
Drug: Taladegib
Drug: Cisplatin
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2016-05-27

Last Posted Date: 2020-08-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 94

Registration Number: NCT02784795

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

and more 8 locations

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Phase 2

Completed

Conditions: Mesothelioma

Interventions: Drug: Cisplatin
Drug: Pemetrexed
Drug: Pembrolizumab

First Posted Date: 2016-05-26

Last Posted Date: 2024-12-10

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 520

Registration Number: NCT02784171

Locations: 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇫🇷
Institut Gustave-Roussy, Villejuif, FR, France
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada

and more 53 locations

Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma

Phase 2

Conditions: Unresectable Localized Soft Tissue Sarcoma

Interventions: Drug: Cisplatin
Drug: Etoposide
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Ifosfamide
Drug: Carboplatin
Radiation: Radiotherapy
Drug: Thiotepa
Drug: Melphalan

First Posted Date: 2016-05-26

Last Posted Date: 2018-09-18

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 41

Registration Number: NCT02784015

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Completed

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: carboplatin
Drug: cisplatin
Drug: 5-FU

First Posted Date: 2016-05-19

Last Posted Date: 2024-05-06

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 413

Registration Number: NCT02778191

Locations: 🇳🇱
VUmc, Amsterdam, Netherlands
🇳🇱
University Medical Center Groningen, Groningen, Netherlands

Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Pembrolizumab
Drug: Cisplatin
Radiation: IMRT

First Posted Date: 2016-05-19

Last Posted Date: 2024-08-01

Lead Sponsor: Dan Zandberg

Target Recruit Count: 80

Registration Number: NCT02777385

Locations: 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma

Phase 1

Completed

Conditions: Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7
Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7

Interventions: Drug: Cisplatin
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab

First Posted Date: 2016-05-18

Last Posted Date: 2022-06-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT02775812

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 66 locations

Response-based Treatment of High-risk Neuroblastoma

Phase 2

Conditions: Newly Diagnosed High Risk Neuroblastoma

Interventions: Drug: Cisplatin
Drug: Doxorubicin
Drug: Etoposide
Drug: Cyclophosphamide
Drug: Ifosfamide
Drug: Carboplatin
Procedure: Tandem HDCT/auto-SCT
Radiation: Radiotherapy
Drug: Interleukin-2
Drug: Isotretinoin
Radiation: MIBG

First Posted Date: 2016-05-13

Last Posted Date: 2016-05-24

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 54

Registration Number: NCT02771743

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC

Phase 3

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Radiation: Radiation Therapy (RT)
Drug: Cisplatin
Drug: Etoposide
Other: Placebo
Drug: Nivolumab

First Posted Date: 2016-05-11

Last Posted Date: 2021-06-02

Lead Sponsor: RTOG Foundation, Inc.

Target Recruit Count: 20

Registration Number: NCT02768558

Locations: 🇺🇸
Virginia Mason, Seattle, Washington, United States
🇺🇸
Mount Sinai Cancer Research Center, Miami Beach, Florida, United States
🇺🇸
Reading Hospital/McGlinn Cancer Institute, West Reading, Pennsylvania, United States

and more 13 locations

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions: Drug: Nivolumab
Drug: Cisplatin
Drug: Cetuximab
Radiation: IMRT

First Posted Date: 2016-05-06

Last Posted Date: 2022-11-29

Lead Sponsor: RTOG Foundation, Inc.

Target Recruit Count: 40

Registration Number: NCT02764593

Locations: 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
UPMC - Shadyside Hospital, Pittsburgh, Pennsylvania, United States

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy